Key Insights
The global Glucagon Market is projected to experience robust growth, reaching an estimated $576.13 million by 2025, driven by a Compound Annual Growth Rate (CAGR) of 6.03% throughout the forecast period of 2025-2033. This expansion is primarily fueled by the increasing prevalence of diabetes worldwide, a condition that necessitates effective management of blood glucose levels. Glucagon plays a critical role in treating hypoglycemia, a common and potentially life-threatening complication of diabetes. The growing awareness among patients and healthcare providers about the benefits of timely glucagon administration for emergency treatment of severe hypoglycemia is a significant market accelerator. Furthermore, advancements in drug delivery systems, particularly in the development of more convenient and user-friendly injection devices and potentially inhaled formulations, are enhancing patient compliance and contributing to market expansion. The rising incidence of type 1 and type 2 diabetes, coupled with an aging global population that is more susceptible to these conditions, creates a sustained demand for glucagon-based therapies.
Glucagon Market Market Size (In Million)
The market is segmented by route of administration, with injections dominating due to their established efficacy and widespread adoption for emergency use. However, the exploration of inhalation as an alternative route holds promise for improved patient comfort and potentially faster systemic absorption, representing a key trend to watch. Application-wise, the primary use of glucagon as a treatment for hypoglycemia is expected to continue its strong trajectory. Its role as a diagnostic aid in specific medical scenarios also contributes to market demand. The distribution channels are a mix of online and offline, with offline channels, including hospitals, pharmacies, and retail outlets, currently holding a larger share due to the critical nature of glucagon for emergency use. However, the increasing adoption of e-pharmacies and online healthcare platforms is expected to boost the online segment's growth. Geographically, North America and Europe are anticipated to be leading markets, driven by high diabetes prevalence and advanced healthcare infrastructures. The Asia Pacific region presents a significant growth opportunity due to its large population base and rising healthcare expenditure.
Glucagon Market Company Market Share
This in-depth report provides a thorough analysis of the global Glucagon Market, offering critical insights into its structure, dynamics, and future trajectory. Designed for industry professionals, researchers, and investors, this report leverages high-ranking keywords and actionable data to enhance strategic decision-making in the rapidly evolving glucagon therapeutics and diagnostics landscape.
Glucagon Market Market Structure & Innovation Trends
The Glucagon Market exhibits a moderate to high concentration, with key players like Novo Nordisk A/S, Xeris Biopharma Holdings Inc., and Amphastar Pharmaceuticals Inc. holding significant market shares. Innovation is a primary driver, fueled by continuous research into novel delivery systems and more effective formulations for treating severe hypoglycemia. Regulatory frameworks, particularly concerning drug approvals and efficacy standards by bodies like the FDA and EMA, play a crucial role in shaping market access and product development. Product substitutes, while limited for acute hypoglycemia management, include alternative glucose-raising agents and intensive insulin therapy adjustments. End-user demographics are increasingly focused on diabetic populations, especially those at higher risk of severe hypoglycemic episodes. Mergers and acquisitions (M&A) are a notable trend, with significant deal values aimed at consolidating market position and expanding product portfolios. For instance, the acquisition of BAQSIMI by Amphastar Pharmaceuticals Inc. in June 2023 signifies strategic moves to acquire established, innovative products.
- Market Concentration: Dominated by a few key pharmaceutical giants, with a growing presence of specialized biotech firms.
- Innovation Drivers: Development of user-friendly delivery devices (autoinjectors, nasal sprays), improved formulation stability, and expanded indications.
- Regulatory Frameworks: Strict approval processes by health authorities, emphasizing safety and efficacy, impacting R&D timelines and market entry.
- Product Substitutes: Limited for emergency hypoglycemia, but includes complex diabetes management strategies.
- End-User Demographics: Primarily patients with Type 1 and Type 2 diabetes prone to severe hypoglycemia, caregivers, and healthcare providers.
- M&A Activities: Strategic acquisitions to gain access to innovative products and technologies, enhancing competitive advantage.
Glucagon Market Market Dynamics & Trends
The Glucagon Market is poised for substantial growth, driven by a confluence of factors including the increasing global prevalence of diabetes mellitus, a rising incidence of severe hypoglycemic events, and advancements in drug delivery technologies. The estimated market size for 2025 is projected to reach approximately $1,500 Million, with a projected Compound Annual Growth Rate (CAGR) of around 7.5% from 2025 to 2033. This robust growth is significantly influenced by the expanding patient pool requiring effective and rapid-acting glucose-raising therapies. Technological disruptions, such as the development of pre-filled autoinjectors and ready-to-use nasal sprays, have revolutionized the administration of glucagon, making it more accessible and user-friendly for both patients and caregivers. Consumer preferences are shifting towards convenience and ease of use, driving demand for these advanced delivery systems. Competitive dynamics are intensifying, with established players investing heavily in R&D and newer entrants focusing on niche applications or innovative technologies. Market penetration is gradually increasing as awareness of glucagon's critical role in emergency hypoglycemia management grows, particularly among healthcare professionals and patient advocacy groups. The market is characterized by a strong emphasis on patient outcomes and quality of life, pushing for more integrated diabetes care solutions.
Dominant Regions & Segments in Glucagon Market
North America currently holds the dominant position in the Glucagon Market, with the United States leading the regional growth. This dominance is attributed to several key factors, including a high prevalence of diabetes, advanced healthcare infrastructure, significant R&D investments, and a robust regulatory environment that supports the approval and adoption of innovative glucagon therapies. The increasing awareness and proactive management of diabetes-related complications, particularly severe hypoglycemia, further bolster market demand in this region.
Route of Administration:
- Injection: Remains the most established and widely adopted route, driven by its proven efficacy and the availability of various injectable formulations. The historical preference for injections, coupled with ongoing improvements in autoinjector technology, ensures its continued dominance.
- Inhalation: Nasal glucagon products have gained significant traction due to their non-invasive nature and ease of administration, offering a competitive alternative to injections. The acquisition of BAQSIMI by Amphastar Pharmaceuticals Inc. highlights the strategic importance of this segment.
Application:
- Hypoglycemia: This segment overwhelmingly leads the market due to the critical need for immediate glucose elevation in patients experiencing severe hypoglycemic episodes, a common and potentially life-threatening complication of diabetes management.
- Diagnostic Aid: While a smaller segment, glucagon's role in certain diagnostic procedures, such as assessing pancreatic endocrine function, contributes to its overall market presence.
Distribution Channel:
- Offline: Traditional brick-and-mortar pharmacies and hospital dispensaries continue to be the primary distribution channels, ensuring widespread accessibility and professional oversight.
- Online: The growing influence of e-pharmacies and direct-to-consumer platforms is expected to see increased penetration, offering convenience for patients and potentially expanding market reach.
Glucagon Market Product Innovations
The Glucagon Market is witnessing a wave of product innovations aimed at enhancing patient convenience, efficacy, and safety. Key developments include the creation of user-friendly pre-filled autoinjectors, such as Ogluo launched by Arecor Therapeutics PLC through its subsidiary Tetris Pharma Ltd. These devices simplify administration, reducing the burden on patients and caregivers. Furthermore, ready-to-use nasal glucagon formulations have emerged as a significant innovation, offering a non-invasive and rapid method for glucose restoration. These advancements address critical needs for faster and more accessible emergency treatments for severe hypoglycemia. Competitive advantages are being carved out through improved formulation stability, longer shelf lives, and user-centric design.
Report Scope & Segmentation Analysis
This report provides a comprehensive analysis of the Glucagon Market, encompassing detailed segmentation across key parameters. The Route of Administration includes Injection and Inhalation. The Injection segment is projected to maintain its dominant position due to established efficacy and technological advancements in autoinjectors. The Inhalation segment is experiencing rapid growth driven by the convenience and non-invasive nature of nasal glucagon products. Under Application, the Hypoglycemia segment is the primary market driver, reflecting the urgent need for effective treatments for low blood sugar events. The Diagnostic Aid segment, while smaller, contributes to the overall market. For Distribution Channel, both Online and Offline channels are analyzed. The Offline segment, encompassing pharmacies and hospitals, currently leads, while the Online segment is projected for significant growth.
Key Drivers of Glucagon Market Growth
Several critical factors are propelling the growth of the Glucagon Market. The escalating global prevalence of diabetes mellitus, a condition that often necessitates glucose-raising therapies to manage severe hypoglycemia, is a primary driver. Technological advancements in drug delivery, particularly the development of convenient and user-friendly autoinjectors and nasal sprays, are significantly enhancing market adoption and patient compliance. Increased awareness among healthcare professionals and patients regarding the immediate need and efficacy of glucagon in emergency situations is also a crucial growth accelerator. Furthermore, supportive regulatory environments in key markets facilitate the approval and commercialization of new glucagon-based products.
Challenges in the Glucagon Market Sector
Despite robust growth prospects, the Glucagon Market faces several challenges. Regulatory hurdles, including stringent approval processes and post-market surveillance, can lead to extended development timelines and increased costs for new products. Supply chain complexities, particularly in ensuring the consistent availability of temperature-sensitive glucagon formulations, can pose logistical challenges. Competitive pressures from established players and emerging biotechs, coupled with the constant need for innovation to differentiate products, create a dynamic market landscape. Pricing pressures and reimbursement policies in different healthcare systems also present potential restraints on market expansion.
Emerging Opportunities in Glucagon Market
The Glucagon Market presents several promising emerging opportunities. The development of novel glucagon formulations with extended stability and improved ease of administration, such as dissolvable films or more advanced inhalation devices, represents a significant technological frontier. Expanding the application of glucagon beyond emergency hypoglycemia treatment to other indications, such as anorexia nervosa or to facilitate diagnostic procedures, could unlock new market segments. Geographic expansion into emerging economies with a growing diabetes burden and improving healthcare infrastructure offers substantial untapped potential. Furthermore, the integration of glucagon delivery devices with continuous glucose monitoring (CGM) systems could lead to more sophisticated and personalized diabetes management solutions, creating a synergistic market opportunity.
Leading Players in the Glucagon Market Market
- Novo Nordisk A/S
- Xeris Biopharma Holdings Inc.
- Amphastar Pharmaceuticals Inc.
- Zealand Pharma A/S
- Fresenius SE & Co KGaA
- Taj Pharmaceuticals Limited
- ILS Inc.
- United Biotech (P) Limited
- Arecor
- Avalon Pharma Private Limited
Key Developments in Glucagon Market Industry
- February 2024: Arecor Therapeutics PLC, through its subsidiary company, Tetris Pharma Ltd, launched Ogluo, a glucagon-prefilled autoinjector pen in the Netherlands. It is indicated to treat severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
- June 2023: Amphastar Pharmaceuticals Inc. acquired BAQSIMI, a ready-to-use glucagon powder administered nasally, from Eli Lilly and Company.
Future Outlook for Glucagon Market Market
The future outlook for the Glucagon Market is exceptionally positive, driven by an anticipated surge in demand for effective and convenient hypoglycemia management solutions. The increasing global diabetes epidemic, coupled with advancements in drug delivery technologies, will continue to fuel market expansion. Investments in research and development for novel glucagon formulations and delivery systems are expected to accelerate, leading to more patient-centric products. Strategic collaborations and acquisitions among key players will likely shape the competitive landscape, aiming to consolidate market share and broaden product portfolios. The growing emphasis on integrated diabetes care and the potential for new therapeutic applications will further bolster future market growth, positioning the Glucagon Market as a vital component of diabetes management for years to come.
Glucagon Market Segmentation
-
1. Route of Administration
- 1.1. Injection
- 1.2. Inhalation
-
2. Application
- 2.1. Hypoglycemia
- 2.2. Diagnostic Aid
-
3. Distribution Channel
- 3.1. Online
- 3.2. Offline
Glucagon Market Segmentation By Geography
-
1. North America
- 1.1. United States
- 1.2. Canada
- 1.3. Mexico
-
2. Europe
- 2.1. Germany
- 2.2. United Kingdom
- 2.3. France
- 2.4. Italy
- 2.5. Spain
- 2.6. Rest of Europe
-
3. Asia Pacific
- 3.1. China
- 3.2. Japan
- 3.3. India
- 3.4. Australia
- 3.5. South Korea
- 3.6. Rest of Asia Pacific
- 4. Rest of the World
Glucagon Market Regional Market Share
Geographic Coverage of Glucagon Market
Glucagon Market REPORT HIGHLIGHTS
| Aspects | Details |
|---|---|
| Study Period | 2020-2034 |
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026-2034 |
| Historical Period | 2020-2025 |
| Growth Rate | CAGR of 6.03% from 2020-2034 |
| Segmentation |
|
Table of Contents
- 1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Objective
- 1.4. Definitions and Assumptions
- 2. Executive Summary
- 2.1. Market Snapshot
- 3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restrains
- 3.3. Market Trends
- 3.4. Market Opportunities
- 4. Market Factor Analysis
- 4.1. Porters Five Forces
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. PESTEL analysis
- 4.3. BCG Analysis
- 4.3.1. Stars (High Growth, High Market Share)
- 4.3.2. Cash Cows (Low Growth, High Market Share)
- 4.3.3. Question Mark (High Growth, Low Market Share)
- 4.3.4. Dogs (Low Growth, Low Market Share)
- 4.4. Ansoff Matrix Analysis
- 4.5. Supply Chain Analysis
- 4.6. Regulatory Landscape
- 4.7. Current Market Potential and Opportunity Assessment (TAM–SAM–SOM Framework)
- 4.8. PRI Analyst Note
- 4.1. Porters Five Forces
- 5. Market Analysis, Insights and Forecast 2021-2033
- 5.1. Market Analysis, Insights and Forecast - by Route of Administration
- 5.1.1. Injection
- 5.1.2. Inhalation
- 5.2. Market Analysis, Insights and Forecast - by Application
- 5.2.1. Hypoglycemia
- 5.2.2. Diagnostic Aid
- 5.3. Market Analysis, Insights and Forecast - by Distribution Channel
- 5.3.1. Online
- 5.3.2. Offline
- 5.4. Market Analysis, Insights and Forecast - by Region
- 5.4.1. North America
- 5.4.2. Europe
- 5.4.3. Asia Pacific
- 5.4.4. Rest of the World
- 5.1. Market Analysis, Insights and Forecast - by Route of Administration
- 6. Global Glucagon Market Analysis, Insights and Forecast, 2021-2033
- 6.1. Market Analysis, Insights and Forecast - by Route of Administration
- 6.1.1. Injection
- 6.1.2. Inhalation
- 6.2. Market Analysis, Insights and Forecast - by Application
- 6.2.1. Hypoglycemia
- 6.2.2. Diagnostic Aid
- 6.3. Market Analysis, Insights and Forecast - by Distribution Channel
- 6.3.1. Online
- 6.3.2. Offline
- 6.1. Market Analysis, Insights and Forecast - by Route of Administration
- 7. North America Glucagon Market Analysis, Insights and Forecast, 2020-2032
- 7.1. Market Analysis, Insights and Forecast - by Route of Administration
- 7.1.1. Injection
- 7.1.2. Inhalation
- 7.2. Market Analysis, Insights and Forecast - by Application
- 7.2.1. Hypoglycemia
- 7.2.2. Diagnostic Aid
- 7.3. Market Analysis, Insights and Forecast - by Distribution Channel
- 7.3.1. Online
- 7.3.2. Offline
- 7.1. Market Analysis, Insights and Forecast - by Route of Administration
- 8. Europe Glucagon Market Analysis, Insights and Forecast, 2020-2032
- 8.1. Market Analysis, Insights and Forecast - by Route of Administration
- 8.1.1. Injection
- 8.1.2. Inhalation
- 8.2. Market Analysis, Insights and Forecast - by Application
- 8.2.1. Hypoglycemia
- 8.2.2. Diagnostic Aid
- 8.3. Market Analysis, Insights and Forecast - by Distribution Channel
- 8.3.1. Online
- 8.3.2. Offline
- 8.1. Market Analysis, Insights and Forecast - by Route of Administration
- 9. Asia Pacific Glucagon Market Analysis, Insights and Forecast, 2020-2032
- 9.1. Market Analysis, Insights and Forecast - by Route of Administration
- 9.1.1. Injection
- 9.1.2. Inhalation
- 9.2. Market Analysis, Insights and Forecast - by Application
- 9.2.1. Hypoglycemia
- 9.2.2. Diagnostic Aid
- 9.3. Market Analysis, Insights and Forecast - by Distribution Channel
- 9.3.1. Online
- 9.3.2. Offline
- 9.1. Market Analysis, Insights and Forecast - by Route of Administration
- 10. Rest of the World Glucagon Market Analysis, Insights and Forecast, 2020-2032
- 10.1. Market Analysis, Insights and Forecast - by Route of Administration
- 10.1.1. Injection
- 10.1.2. Inhalation
- 10.2. Market Analysis, Insights and Forecast - by Application
- 10.2.1. Hypoglycemia
- 10.2.2. Diagnostic Aid
- 10.3. Market Analysis, Insights and Forecast - by Distribution Channel
- 10.3.1. Online
- 10.3.2. Offline
- 10.1. Market Analysis, Insights and Forecast - by Route of Administration
- 11. Competitive Analysis
- 11.1. Company Profiles
- 11.1.1 Novo Nordisk A/S
- 11.1.1.1. Company Overview
- 11.1.1.2. Products
- 11.1.1.3. Company Financials
- 11.1.1.4. SWOT Analysis
- 11.1.2 Xeris Biopharma Holdings Inc
- 11.1.2.1. Company Overview
- 11.1.2.2. Products
- 11.1.2.3. Company Financials
- 11.1.2.4. SWOT Analysis
- 11.1.3 Amphastar Pharmaceuticals Inc
- 11.1.3.1. Company Overview
- 11.1.3.2. Products
- 11.1.3.3. Company Financials
- 11.1.3.4. SWOT Analysis
- 11.1.4 Zealand Pharma A/S
- 11.1.4.1. Company Overview
- 11.1.4.2. Products
- 11.1.4.3. Company Financials
- 11.1.4.4. SWOT Analysis
- 11.1.5 Fresenius SE & Co KGaA
- 11.1.5.1. Company Overview
- 11.1.5.2. Products
- 11.1.5.3. Company Financials
- 11.1.5.4. SWOT Analysis
- 11.1.6 Taj Pharmaceuticals Limited
- 11.1.6.1. Company Overview
- 11.1.6.2. Products
- 11.1.6.3. Company Financials
- 11.1.6.4. SWOT Analysis
- 11.1.7 ILS Inc
- 11.1.7.1. Company Overview
- 11.1.7.2. Products
- 11.1.7.3. Company Financials
- 11.1.7.4. SWOT Analysis
- 11.1.8 United Biotech (P) Limited
- 11.1.8.1. Company Overview
- 11.1.8.2. Products
- 11.1.8.3. Company Financials
- 11.1.8.4. SWOT Analysis
- 11.1.9 Arecor
- 11.1.9.1. Company Overview
- 11.1.9.2. Products
- 11.1.9.3. Company Financials
- 11.1.9.4. SWOT Analysis
- 11.1.10 Avalon Pharma Private Limited*List Not Exhaustive
- 11.1.10.1. Company Overview
- 11.1.10.2. Products
- 11.1.10.3. Company Financials
- 11.1.10.4. SWOT Analysis
- 11.1.1 Novo Nordisk A/S
- 11.2. Market Entropy
- 11.2.1 Company's Key Areas Served
- 11.2.2 Recent Developments
- 11.3. Company Market Share Analysis 2025
- 11.3.1 Top 5 Companies Market Share Analysis
- 11.3.2 Top 3 Companies Market Share Analysis
- 11.4. List of Potential Customers
- 12. Research Methodology
List of Figures
- Figure 1: Global Glucagon Market Revenue Breakdown (Million, %) by Region 2025 & 2033
- Figure 2: Global Glucagon Market Volume Breakdown (Million, %) by Region 2025 & 2033
- Figure 3: North America Glucagon Market Revenue (Million), by Route of Administration 2025 & 2033
- Figure 4: North America Glucagon Market Volume (Million), by Route of Administration 2025 & 2033
- Figure 5: North America Glucagon Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 6: North America Glucagon Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 7: North America Glucagon Market Revenue (Million), by Application 2025 & 2033
- Figure 8: North America Glucagon Market Volume (Million), by Application 2025 & 2033
- Figure 9: North America Glucagon Market Revenue Share (%), by Application 2025 & 2033
- Figure 10: North America Glucagon Market Volume Share (%), by Application 2025 & 2033
- Figure 11: North America Glucagon Market Revenue (Million), by Distribution Channel 2025 & 2033
- Figure 12: North America Glucagon Market Volume (Million), by Distribution Channel 2025 & 2033
- Figure 13: North America Glucagon Market Revenue Share (%), by Distribution Channel 2025 & 2033
- Figure 14: North America Glucagon Market Volume Share (%), by Distribution Channel 2025 & 2033
- Figure 15: North America Glucagon Market Revenue (Million), by Country 2025 & 2033
- Figure 16: North America Glucagon Market Volume (Million), by Country 2025 & 2033
- Figure 17: North America Glucagon Market Revenue Share (%), by Country 2025 & 2033
- Figure 18: North America Glucagon Market Volume Share (%), by Country 2025 & 2033
- Figure 19: Europe Glucagon Market Revenue (Million), by Route of Administration 2025 & 2033
- Figure 20: Europe Glucagon Market Volume (Million), by Route of Administration 2025 & 2033
- Figure 21: Europe Glucagon Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 22: Europe Glucagon Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 23: Europe Glucagon Market Revenue (Million), by Application 2025 & 2033
- Figure 24: Europe Glucagon Market Volume (Million), by Application 2025 & 2033
- Figure 25: Europe Glucagon Market Revenue Share (%), by Application 2025 & 2033
- Figure 26: Europe Glucagon Market Volume Share (%), by Application 2025 & 2033
- Figure 27: Europe Glucagon Market Revenue (Million), by Distribution Channel 2025 & 2033
- Figure 28: Europe Glucagon Market Volume (Million), by Distribution Channel 2025 & 2033
- Figure 29: Europe Glucagon Market Revenue Share (%), by Distribution Channel 2025 & 2033
- Figure 30: Europe Glucagon Market Volume Share (%), by Distribution Channel 2025 & 2033
- Figure 31: Europe Glucagon Market Revenue (Million), by Country 2025 & 2033
- Figure 32: Europe Glucagon Market Volume (Million), by Country 2025 & 2033
- Figure 33: Europe Glucagon Market Revenue Share (%), by Country 2025 & 2033
- Figure 34: Europe Glucagon Market Volume Share (%), by Country 2025 & 2033
- Figure 35: Asia Pacific Glucagon Market Revenue (Million), by Route of Administration 2025 & 2033
- Figure 36: Asia Pacific Glucagon Market Volume (Million), by Route of Administration 2025 & 2033
- Figure 37: Asia Pacific Glucagon Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 38: Asia Pacific Glucagon Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 39: Asia Pacific Glucagon Market Revenue (Million), by Application 2025 & 2033
- Figure 40: Asia Pacific Glucagon Market Volume (Million), by Application 2025 & 2033
- Figure 41: Asia Pacific Glucagon Market Revenue Share (%), by Application 2025 & 2033
- Figure 42: Asia Pacific Glucagon Market Volume Share (%), by Application 2025 & 2033
- Figure 43: Asia Pacific Glucagon Market Revenue (Million), by Distribution Channel 2025 & 2033
- Figure 44: Asia Pacific Glucagon Market Volume (Million), by Distribution Channel 2025 & 2033
- Figure 45: Asia Pacific Glucagon Market Revenue Share (%), by Distribution Channel 2025 & 2033
- Figure 46: Asia Pacific Glucagon Market Volume Share (%), by Distribution Channel 2025 & 2033
- Figure 47: Asia Pacific Glucagon Market Revenue (Million), by Country 2025 & 2033
- Figure 48: Asia Pacific Glucagon Market Volume (Million), by Country 2025 & 2033
- Figure 49: Asia Pacific Glucagon Market Revenue Share (%), by Country 2025 & 2033
- Figure 50: Asia Pacific Glucagon Market Volume Share (%), by Country 2025 & 2033
- Figure 51: Rest of the World Glucagon Market Revenue (Million), by Route of Administration 2025 & 2033
- Figure 52: Rest of the World Glucagon Market Volume (Million), by Route of Administration 2025 & 2033
- Figure 53: Rest of the World Glucagon Market Revenue Share (%), by Route of Administration 2025 & 2033
- Figure 54: Rest of the World Glucagon Market Volume Share (%), by Route of Administration 2025 & 2033
- Figure 55: Rest of the World Glucagon Market Revenue (Million), by Application 2025 & 2033
- Figure 56: Rest of the World Glucagon Market Volume (Million), by Application 2025 & 2033
- Figure 57: Rest of the World Glucagon Market Revenue Share (%), by Application 2025 & 2033
- Figure 58: Rest of the World Glucagon Market Volume Share (%), by Application 2025 & 2033
- Figure 59: Rest of the World Glucagon Market Revenue (Million), by Distribution Channel 2025 & 2033
- Figure 60: Rest of the World Glucagon Market Volume (Million), by Distribution Channel 2025 & 2033
- Figure 61: Rest of the World Glucagon Market Revenue Share (%), by Distribution Channel 2025 & 2033
- Figure 62: Rest of the World Glucagon Market Volume Share (%), by Distribution Channel 2025 & 2033
- Figure 63: Rest of the World Glucagon Market Revenue (Million), by Country 2025 & 2033
- Figure 64: Rest of the World Glucagon Market Volume (Million), by Country 2025 & 2033
- Figure 65: Rest of the World Glucagon Market Revenue Share (%), by Country 2025 & 2033
- Figure 66: Rest of the World Glucagon Market Volume Share (%), by Country 2025 & 2033
List of Tables
- Table 1: Global Glucagon Market Revenue Million Forecast, by Route of Administration 2020 & 2033
- Table 2: Global Glucagon Market Volume Million Forecast, by Route of Administration 2020 & 2033
- Table 3: Global Glucagon Market Revenue Million Forecast, by Application 2020 & 2033
- Table 4: Global Glucagon Market Volume Million Forecast, by Application 2020 & 2033
- Table 5: Global Glucagon Market Revenue Million Forecast, by Distribution Channel 2020 & 2033
- Table 6: Global Glucagon Market Volume Million Forecast, by Distribution Channel 2020 & 2033
- Table 7: Global Glucagon Market Revenue Million Forecast, by Region 2020 & 2033
- Table 8: Global Glucagon Market Volume Million Forecast, by Region 2020 & 2033
- Table 9: Global Glucagon Market Revenue Million Forecast, by Route of Administration 2020 & 2033
- Table 10: Global Glucagon Market Volume Million Forecast, by Route of Administration 2020 & 2033
- Table 11: Global Glucagon Market Revenue Million Forecast, by Application 2020 & 2033
- Table 12: Global Glucagon Market Volume Million Forecast, by Application 2020 & 2033
- Table 13: Global Glucagon Market Revenue Million Forecast, by Distribution Channel 2020 & 2033
- Table 14: Global Glucagon Market Volume Million Forecast, by Distribution Channel 2020 & 2033
- Table 15: Global Glucagon Market Revenue Million Forecast, by Country 2020 & 2033
- Table 16: Global Glucagon Market Volume Million Forecast, by Country 2020 & 2033
- Table 17: United States Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 18: United States Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 19: Canada Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 20: Canada Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 21: Mexico Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 22: Mexico Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 23: Global Glucagon Market Revenue Million Forecast, by Route of Administration 2020 & 2033
- Table 24: Global Glucagon Market Volume Million Forecast, by Route of Administration 2020 & 2033
- Table 25: Global Glucagon Market Revenue Million Forecast, by Application 2020 & 2033
- Table 26: Global Glucagon Market Volume Million Forecast, by Application 2020 & 2033
- Table 27: Global Glucagon Market Revenue Million Forecast, by Distribution Channel 2020 & 2033
- Table 28: Global Glucagon Market Volume Million Forecast, by Distribution Channel 2020 & 2033
- Table 29: Global Glucagon Market Revenue Million Forecast, by Country 2020 & 2033
- Table 30: Global Glucagon Market Volume Million Forecast, by Country 2020 & 2033
- Table 31: Germany Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 32: Germany Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 33: United Kingdom Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 34: United Kingdom Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 35: France Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 36: France Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 37: Italy Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 38: Italy Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 39: Spain Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 40: Spain Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 41: Rest of Europe Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 42: Rest of Europe Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 43: Global Glucagon Market Revenue Million Forecast, by Route of Administration 2020 & 2033
- Table 44: Global Glucagon Market Volume Million Forecast, by Route of Administration 2020 & 2033
- Table 45: Global Glucagon Market Revenue Million Forecast, by Application 2020 & 2033
- Table 46: Global Glucagon Market Volume Million Forecast, by Application 2020 & 2033
- Table 47: Global Glucagon Market Revenue Million Forecast, by Distribution Channel 2020 & 2033
- Table 48: Global Glucagon Market Volume Million Forecast, by Distribution Channel 2020 & 2033
- Table 49: Global Glucagon Market Revenue Million Forecast, by Country 2020 & 2033
- Table 50: Global Glucagon Market Volume Million Forecast, by Country 2020 & 2033
- Table 51: China Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 52: China Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 53: Japan Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 54: Japan Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 55: India Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 56: India Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 57: Australia Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 58: Australia Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 59: South Korea Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 60: South Korea Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 61: Rest of Asia Pacific Glucagon Market Revenue (Million) Forecast, by Application 2020 & 2033
- Table 62: Rest of Asia Pacific Glucagon Market Volume (Million) Forecast, by Application 2020 & 2033
- Table 63: Global Glucagon Market Revenue Million Forecast, by Route of Administration 2020 & 2033
- Table 64: Global Glucagon Market Volume Million Forecast, by Route of Administration 2020 & 2033
- Table 65: Global Glucagon Market Revenue Million Forecast, by Application 2020 & 2033
- Table 66: Global Glucagon Market Volume Million Forecast, by Application 2020 & 2033
- Table 67: Global Glucagon Market Revenue Million Forecast, by Distribution Channel 2020 & 2033
- Table 68: Global Glucagon Market Volume Million Forecast, by Distribution Channel 2020 & 2033
- Table 69: Global Glucagon Market Revenue Million Forecast, by Country 2020 & 2033
- Table 70: Global Glucagon Market Volume Million Forecast, by Country 2020 & 2033
Frequently Asked Questions
1. What is the projected Compound Annual Growth Rate (CAGR) of the Glucagon Market?
The projected CAGR is approximately 6.03%.
2. Which companies are prominent players in the Glucagon Market?
Key companies in the market include Novo Nordisk A/S, Xeris Biopharma Holdings Inc, Amphastar Pharmaceuticals Inc, Zealand Pharma A/S, Fresenius SE & Co KGaA, Taj Pharmaceuticals Limited, ILS Inc, United Biotech (P) Limited, Arecor, Avalon Pharma Private Limited*List Not Exhaustive.
3. What are the main segments of the Glucagon Market?
The market segments include Route of Administration, Application, Distribution Channel.
4. Can you provide details about the market size?
The market size is estimated to be USD 576.13 Million as of 2022.
5. What are some drivers contributing to market growth?
Increasing Burden of Diabetes; Reimbursement Offered on Glucagon Products.
6. What are the notable trends driving market growth?
Hypoglycemia Segment is Expected to Witness Significant Growth During the Forecast Period.
7. Are there any restraints impacting market growth?
Increasing Burden of Diabetes; Reimbursement Offered on Glucagon Products.
8. Can you provide examples of recent developments in the market?
February 2024: Arecor Therapeutics PLC, through its subsidiary company, Tetris Pharma Ltd, launched Ogluo, a glucagon-prefilled autoinjector pen in the Netherlands. It is indicated to treat severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus.
9. What pricing options are available for accessing the report?
Pricing options include single-user, multi-user, and enterprise licenses priced at USD 4750, USD 5250, and USD 8750 respectively.
10. Is the market size provided in terms of value or volume?
The market size is provided in terms of value, measured in Million and volume, measured in Million.
11. Are there any specific market keywords associated with the report?
Yes, the market keyword associated with the report is "Glucagon Market," which aids in identifying and referencing the specific market segment covered.
12. How do I determine which pricing option suits my needs best?
The pricing options vary based on user requirements and access needs. Individual users may opt for single-user licenses, while businesses requiring broader access may choose multi-user or enterprise licenses for cost-effective access to the report.
13. Are there any additional resources or data provided in the Glucagon Market report?
While the report offers comprehensive insights, it's advisable to review the specific contents or supplementary materials provided to ascertain if additional resources or data are available.
14. How can I stay updated on further developments or reports in the Glucagon Market?
To stay informed about further developments, trends, and reports in the Glucagon Market, consider subscribing to industry newsletters, following relevant companies and organizations, or regularly checking reputable industry news sources and publications.
Methodology
Step 1 - Identification of Relevant Samples Size from Population Database
Step 2 - Approaches for Defining Global Market Size (Value, Volume* & Price*)
Note*: In applicable scenarios
Step 3 - Data Sources
Primary Research
- Web Analytics
- Survey Reports
- Research Institute
- Latest Research Reports
- Opinion Leaders
Secondary Research
- Annual Reports
- White Paper
- Latest Press Release
- Industry Association
- Paid Database
- Investor Presentations
Step 4 - Data Triangulation
Involves using different sources of information in order to increase the validity of a study
These sources are likely to be stakeholders in a program - participants, other researchers, program staff, other community members, and so on.
Then we put all data in single framework & apply various statistical tools to find out the dynamic on the market.
During the analysis stage, feedback from the stakeholder groups would be compared to determine areas of agreement as well as areas of divergence
